GO:0071875 adrenergic receptor signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0071875 adrenergic receptor signaling pathway is a biological process defined as a G protein-coupled receptor signaling pathway initiated by ligand binding to an adrenergic receptor on the target cell surface and ending with regulation of a downstream cellular process.
• Adrenergic receptors are GPCRs that respond to catecholamines such as norepinephrine and epinephrine and couple to heterotrimeric G proteins to modulate diverse cellular responses.
• The pathway is central to cardiovascular physiology and disease, including heart failure, where beta-adrenergic receptor signaling is a major therapeutic target.
• Adrenergic signaling extends beyond the cardiovascular system, influencing neuroinflammation, tau pathology, sleep-related ovarian follicle activation, and brain-to-lung immune communication.
• Key genes include ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, GNAS, GNAI1, GRK2, ARRB1, and ARRB2.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable causal dissection of adrenergic receptor signaling in disease and drug response.
Description
The adrenergic receptor signaling pathway (GO:0071875) is a biological process in which a ligand binds to an adrenergic receptor on the surface of a target cell and initiates a G protein-coupled receptor signaling cascade that ultimately regulates downstream cellular processes. Adrenergic receptors are activated by endogenous catecholamines, primarily norepinephrine and epinephrine, and they mediate rapid physiological responses across the cardiovascular, nervous, immune, and reproductive systems. Because this pathway is a GPCR signaling module, it is a paradigm for understanding how extracellular signals are converted into intracellular second messengers and transcriptional programs. The pathway is clinically important because dysregulated adrenergic signaling contributes to heart failure, arrhythmias, neuroinflammation, tauopathy, and even ovarian follicle activation under sleep deprivation. Beta-adrenergic receptor signaling in particular has been extensively studied in cardiac physiology and disease, where it is targeted by beta-blockers and other pharmacological agents. Recent work has also revealed non-canonical adrenergic signaling mechanisms and crosstalk with pathways such as Hippo signaling, expanding the conceptual scope of GO:0071875. For researchers, GO:0071875 provides a precise ontological anchor for annotating genes, interpreting transcriptomic and proteomic data, and designing mechanistic experiments. The pathway is initiated by ligand binding to adrenergic receptors, proceeds through G protein activation and effector modulation, and ends with regulation of downstream cellular processes such as contraction, metabolism, gene expression, and inflammation. Understanding its components and regulatory logic is essential for both basic discovery and therapeutic development.
adrenergic receptor signaling pathway At A Glance
| GO ID | GO:0071875 |
|---|---|
| GO term | adrenergic receptor signaling pathway |
| Ontology | biological_process |
| Synonym | adrenergic receptor signalling pathway; adrenoceptor signaling pathway |
| Major function | G protein-coupled receptor signaling initiated by catecholamine binding to adrenergic receptors, leading to regulation of downstream cellular processes |
| Ligands | Epinephrine, norepinephrine, and synthetic adrenergic agonists |
| Receptor family | Adrenergic receptors (ADRA1A/B/D, ADRA2A/B/C, ADRB1/2/3), which are GPCRs |
| Downstream effectors | Heterotrimeric G proteins (Gs, Gi/o, Gq/11), adenylyl cyclase, phospholipase C, ion channels, and arrestin-mediated pathways |
| Related diseases | Heart failure, neuroinflammation, tauopathy, sleep-related ovarian dysfunction, pulmonary inflammation |
What Is GO:0071875?
GO:0071875 adrenergic receptor signaling pathway is defined as a G protein-coupled receptor signaling pathway initiated by a ligand binding to an adrenergic receptor on the surface of a target cell, and ending with the regulation of a downstream cellular process. In other words, it is the entire sequence of molecular events that begins when an adrenergic receptor binds a ligand such as epinephrine or norepinephrine and culminates in changes to cell behavior, metabolism, gene expression, or other downstream functions.
Why Is adrenergic receptor signaling pathway Important in Cell Biology?
GO:0071875 is important because adrenergic receptor signaling is one of the most extensively studied GPCR pathways in human physiology and disease. It controls heart rate and contractility, vascular tone, airway tone, metabolism, immune cell activity, and neuronal function. Dysregulation of this pathway is implicated in heart failure, where beta-adrenergic receptor signaling is a central pathophysiological mechanism and therapeutic target. Beyond the cardiovascular system, adrenergic signaling modulates neuroinflammation and tau pathology in Alzheimer's disease models, influences ovarian primordial follicle activation under sleep deprivation, and mediates brain-to-lung immune communication through ADRB2 on interstitial macrophages. Thus, GO:0071875 is a critical node for understanding both normal physiology and multiple human diseases.
• Central to cardiovascular physiology: beta-adrenergic receptor signaling regulates heart rate, contractility, and remodeling, and is a major target in heart failure therapy.
• Implicated in heart failure pathophysiology and metabolic therapy through crosstalk with Hippo pathway signaling.
• Modulates neuroinflammation and tauopathy via alpha1-adrenergic receptor and STING/NF-kB/NLRP3 signaling in Alzheimer's disease models.
• Regulates ovarian primordial follicle activation under sleep deprivation through beta2-adrenergic receptor signaling.
• Mediates brain-to-lung communication via GABAergic neurons and ADRB2-positive interstitial macrophages in pulmonary inflammation.
• Provides a paradigm for GPCR signaling mechanisms, including canonical G protein pathways and non-canonical beta-arrestin-mediated signaling.
• Subcellular compartmentalization of beta-adrenergic receptor signaling is critical for cardiac physiology and disease.
• Serves as a target for pharmacological interventions such as beta-blockers and adrenergic agonists.
• Offers opportunities for CRISPR-based functional genomics to dissect receptor-specific and tissue-specific roles.
• Enables cross-disciplinary research linking neuroscience, immunology, cardiology, and reproductive biology.
What Happens During adrenergic receptor signaling pathway?
Ligand binding and receptor activation
In simple terms: A chemical messenger such as adrenaline docks onto a receptor on the cell surface, switching the receptor on.
The pathway begins when an agonist ligand, typically epinephrine or norepinephrine, binds to the orthosteric site of an adrenergic receptor on the target cell surface. Adrenergic receptors are members of the G protein-coupled receptor superfamily and undergo conformational changes upon agonist binding that enable them to act as guanine nucleotide exchange factors for heterotrimeric G proteins. This ligand-receptor interaction is the initiating event that defines GO:0071875 and determines the specificity of downstream signaling.
G protein activation and effector modulation
In simple terms: The activated receptor turns on a molecular switch inside the cell, which then flips other switches to change cell behavior.
Activated adrenergic receptors catalyze the exchange of GDP for GTP on the alpha subunit of heterotrimeric G proteins, leading to dissociation of G-alpha-GTP from G-beta-gamma dimers. Different adrenergic receptor subtypes couple preferentially to Gs, Gi/o, or Gq/11 proteins, thereby activating or inhibiting adenylyl cyclase, modulating phospholipase C, and influencing ion channels. For example, beta-adrenergic receptors typically couple to Gs to stimulate cAMP production, while alpha2-adrenergic receptors couple to Gi/o to inhibit cAMP production. This G protein-mediated effector modulation is a core step in the pathway.
Second messenger generation and downstream kinase cascades
In simple terms: The switches inside the cell create small messenger molecules that amplify the signal and activate enzymes that change cell function.
G protein activation leads to the production or modulation of second messengers such as cyclic AMP (cAMP), inositol trisphosphate (IP3), diacylglycerol (DAG), and calcium. cAMP activates protein kinase A (PKA), which phosphorylates numerous substrates including ion channels, transcription factors, and metabolic enzymes. In parallel, G-beta-gamma subunits can directly modulate ion channels and activate signaling enzymes. These second messenger and kinase cascades convert the initial receptor signal into a broad range of cellular responses, including changes in contractility, metabolism, gene expression, and secretion.
Receptor desensitization, internalization, and non-canonical signaling
In simple terms: After the signal is sent, the receptor is turned off or pulled inside the cell, and sometimes it sends a second, different signal.
Following activation, adrenergic receptors are phosphorylated by G protein-coupled receptor kinases (GRKs) and bind arrestins, which uncouple the receptor from G proteins and promote internalization. Beta-arrestin binding can also initiate non-canonical signaling pathways, such as activation of extracellular signal-regulated kinases (ERKs) and other kinases, independent of G protein activation. This desensitization and non-canonical signaling are essential for terminating the response and for shaping the duration and quality of downstream cellular regulation.
Regulation of downstream cellular processes
In simple terms: The signal ultimately changes what the cell does, such as beating harder, releasing chemicals, or turning genes on and off.
The terminal step of GO:0071875 is the regulation of downstream cellular processes, which can include contraction, relaxation, secretion, metabolism, gene transcription, cell growth, and inflammation. For example, beta-adrenergic signaling in cardiomyocytes increases contractility and can drive pathological remodeling in heart failure. In immune cells, ADRB2 signaling modulates inflammatory cytokine production and macrophage function. In the ovary, beta2-adrenergic receptor signaling triggers excessive activation of primordial follicles under sleep deprivation. These diverse outputs illustrate how a single GPCR pathway can regulate context-specific cellular processes.
Key Genes Involved in GO:0071875 adrenergic receptor signaling pathway
The following genes encode receptors, G proteins, and regulatory proteins that are core components or modulators of the adrenergic receptor signaling pathway (GO:0071875).
| Gene | Major Role | Research Relevance |
|---|---|---|
| ADRB1 | Beta1-adrenergic receptor; couples to Gs to stimulate cAMP; major mediator of cardiac contractility | Target in heart failure and cardiac physiology |
| ADRB2 | Beta2-adrenergic receptor; couples to Gs; expressed in airway smooth muscle, immune cells, and many tissues | Implicated in pulmonary inflammation and brain-to-lung signaling; sleep-related ovarian follicle activation |
| ADRB3 | Beta3-adrenergic receptor; involved in lipolysis and metabolic regulation | Metabolic and cardiovascular research |
| ADRA1A | Alpha1A-adrenergic receptor; couples to Gq/11 to activate phospholipase C | Neuroinflammation and tauopathy research |
| ADRA1B | Alpha1B-adrenergic receptor; mediates Gq/11 signaling | Cardiovascular and neuronal function |
| ADRA1D | Alpha1D-adrenergic receptor; Gq/11-coupled | Vascular and neuronal signaling |
| ADRA2A | Alpha2A-adrenergic receptor; couples to Gi/o to inhibit cAMP | Presynaptic regulation and metabolic studies |
| ADRA2B | Alpha2B-adrenergic receptor; Gi/o-coupled | Vascular and neuronal research |
| ADRA2C | Alpha2C-adrenergic receptor; Gi/o-coupled | Cardiovascular and behavioral studies |
| GNAS | Gs alpha subunit; stimulates adenylyl cyclase downstream of beta-adrenergic receptors | Core effector of beta-adrenergic signaling |
| GNAI1 | Gi alpha subunit; inhibits adenylyl cyclase downstream of alpha2-adrenergic receptors | Negative regulation of cAMP |
| GRK2 | G protein-coupled receptor kinase 2; phosphorylates activated adrenergic receptors to promote desensitization | Regulator of receptor desensitization in heart failure |
| ARRB1 | Beta-arrestin 1; mediates receptor desensitization and non-canonical signaling | Non-canonical adrenergic signaling research |
| ARRB2 | Beta-arrestin 2; mediates receptor internalization and ERK activation | Biased agonism and signaling studies |
| PRKACA | Catalytic subunit of PKA; phosphorylates downstream targets in response to cAMP | Second messenger effector in adrenergic signaling |
| ADCY5 | Adenylyl cyclase 5; produces cAMP in response to Gs activation | Cardiac and metabolic adrenergic signaling |
| ADRBK1 | Another name for GRK2; regulates beta-adrenergic receptor phosphorylation | Desensitization and heart failure research |
How Is adrenergic receptor signaling pathway Regulated?
Adrenergic receptor signaling is tightly regulated at multiple levels. Receptor desensitization is mediated by GRK-mediated phosphorylation and beta-arrestin binding, which uncouple receptors from G proteins and promote internalization. Subcellular compartmentalization of beta-adrenergic receptors and their downstream effectors is critical for shaping signaling specificity in cardiac physiology and disease. Crosstalk with other pathways, such as Hippo signaling, modulates beta-adrenergic responses in heart failure and metabolic therapy. Additionally, alpha1-adrenergic receptor signaling can regulate neuroinflammation through the STING/NF-kB/NLRP3 pathway, indicating intersection with innate immune signaling. These regulatory mechanisms ensure that adrenergic signals are appropriately terminated and integrated with other cellular inputs.
adrenergic receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ADRB1 | Heart failure, cardiac contractility | Cardiomyocyte-specific knockout or point-mutation models |
| ADRB2 | Pulmonary inflammation, sleep-related ovarian follicle activation | Macrophage-specific knockout or ovarian overexpression models |
| ADRA1A | Tauopathy, neuroinflammation in Alzheimer's disease | Neuron-specific knockout or knock-in models |
| GRK2 | Heart failure, receptor desensitization | Cardiac-specific knockout or kinase-dead knock-in |
| ARRB2 | Biased agonism, cardiac signaling | Knockout or tagged knock-in for signaling studies |
Heart failure and cardiovascular disease
Beta-adrenergic receptor signaling is a central driver of cardiac pathophysiology in heart failure. Chronic overactivation of beta-adrenergic receptors leads to maladaptive remodeling, cardiomyocyte apoptosis, and reduced cardiac function. Beta-blockers, which antagonize beta-adrenergic receptors, are a cornerstone of heart failure therapy. Recent research has identified crosstalk between beta-adrenergic and Hippo pathway signaling as a potential therapeutic target in heart failure and metabolic therapy. Subcellular localization of beta-adrenergic receptors also influences disease progression, highlighting the importance of compartmentalized signaling.
Neuroinflammation and Alzheimer's disease
Alpha1-adrenergic receptor signaling modulates neuroinflammation and tau pathology in Alzheimer's disease models. Modulation of neuronal alpha1-adrenergic receptors reduces tauopathy and neuroinflammation by inhibiting the STING/NF-kB/NLRP3 signaling pathway in Alzheimer's disease mice. This suggests that adrenergic receptor signaling is not only a cardiovascular target but also a potential therapeutic node in neurodegenerative disease.
Pulmonary inflammation and brain-to-lung communication
A brain-to-lung signal from GABAergic neurons to ADRB2-positive interstitial macrophages promotes pulmonary inflammatory responses. This demonstrates that adrenergic receptor signaling mediates neuroimmune communication and can influence lung inflammation. Targeting ADRB2 in interstitial macrophages may offer new avenues for treating pulmonary inflammatory diseases.
Reproductive biology and sleep deprivation
Sleep deprivation triggers excessive activation of ovarian primordial follicles via beta2-adrenergic receptor signaling. This finding links adrenergic signaling to reproductive aging and ovarian function, suggesting that beta2-adrenergic receptor antagonists or modulators could be explored for preserving ovarian reserve under conditions of sleep disruption.
From adrenergic receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does ADRB1 mediate cardiac contractility in vivo? | Cardiomyocyte-specific ADRB1 knockout mouse |
| Does ADRB2 on macrophages drive pulmonary inflammation? | Macrophage-specific ADRB2 knockout or conditional knock-in |
| Does alpha1-adrenergic receptor modulation affect tau pathology? | Neuron-specific ADRA1A knockout or point-mutation knock-in |
| Does beta2-adrenergic receptor signaling regulate ovarian follicle activation? | Ovarian-specific ADRB2 overexpression or knockout |
| How does GRK2 phosphorylation regulate receptor desensitization? | GRK2 kinase-dead knock-in or knockout cell lines |
| What is the role of beta-arrestin in non-canonical signaling? | ARRB1/ARRB2 double knockout or tagged knock-in |
How to Study the adrenergic receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of receptor or effector gene function | Determine causal role of ADRB1/ADRB2 in disease models |
| cAMP assay | Intracellular cyclic AMP levels | Measure Gs-coupled receptor activation |
| Calcium imaging | Intracellular calcium flux | Measure Gq-coupled receptor activation |
| RNA-seq | Transcriptome-wide gene expression changes | Identify downstream transcriptional programs |
| Proteomics | Protein abundance and post-translational modifications | Discover signaling effectors and feedback |
| FRET biosensors | Real-time kinase activity and second messengers | Study compartmentalized signaling |
| Immunoblotting | Phosphorylation of downstream targets (e.g., ERK, PKA substrates) | Confirm pathway activation |
| Co-immunoprecipitation | Protein-protein interactions | Study receptor-G protein or arrestin complexes |
Genetic knockout and knockdown
CRISPR-Cas9 knockout of adrenergic receptor genes (ADRB1, ADRB2, ADRA1A, etc.) in cell lines or animal models enables loss-of-function studies to determine receptor-specific contributions to downstream signaling. RNA interference and CRISPR interference can complement knockout approaches for acute knockdown. These methods are essential for dissecting the roles of individual receptor subtypes in complex physiological processes.
Biochemical assays for second messengers
Measurement of cAMP, IP3, calcium flux, and kinase activity (e.g., PKA, ERK) provides quantitative readouts of adrenergic receptor signaling activation. These assays can be combined with receptor agonists and antagonists to determine coupling specificity and potency. Such biochemical approaches are foundational for characterizing pathway dynamics.
Transcriptomic and proteomic profiling
RNA sequencing and proteomics can identify downstream transcriptional and post-translational changes induced by adrenergic receptor activation or inhibition. These unbiased approaches reveal novel effectors and feedback mechanisms. Integrating multi-omics data with pathway annotation (GO:0071875) helps contextualize findings within known signaling networks.
Imaging and subcellular localization
Fluorescence microscopy, FRET biosensors, and live-cell imaging can visualize receptor trafficking, compartmentalized cAMP signals, and protein-protein interactions in real time. These techniques are particularly valuable for studying subcellular beta-adrenergic receptor signaling in cardiomyocytes and neurons.
How CRISPR Can Be Used to Study GO:0071875 adrenergic receptor signaling pathway
Knockout
CRISPR knockout of adrenergic receptor genes or downstream effectors (e.g., ADRB2, ADRA1A, GNAS) provides definitive loss-of-function models to test causality in disease processes such as pulmonary inflammation, tauopathy, and ovarian follicle activation. Knockout cell lines and animal models are essential for validating drug targets and understanding receptor-specific contributions.
Point Mutation
CRISPR point mutation can introduce specific amino acid substitutions in adrenergic receptors to study ligand binding, G protein coupling, or phosphorylation sites. For example, mutating GRK phosphorylation sites in ADRB2 can reveal their role in desensitization. Point mutations in G protein subunits can also dissect coupling specificity.
Knock-in
CRISPR knock-in of tagged adrenergic receptors (e.g., HA-tagged ADRB2) or reporter genes enables tracking of receptor localization, trafficking, and interaction partners in native contexts. Knock-in of disease-associated variants can model human genetic contributions to adrenergic signaling dysfunction.
Overexpression
CRISPR-mediated overexpression or cDNA-based overexpression of adrenergic receptors or their effectors can amplify signaling to study downstream consequences, such as cardiac hypertrophy or ovarian follicle activation. Overexpression models are useful for gain-of-function studies and for testing pharmacological interventions.
How EDITGENE Supports adrenergic receptor signaling pathway Research
Researchers studying adrenergic receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in a specific disease or cellular process. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell and animal models, enabling rigorous functional validation of genes within GO:0071875.
Contact EDITGENE today to design your custom CRISPR model for adrenergic receptor signaling pathway research.
Frequently Asked Questions About adrenergic receptor signaling pathway
What is GO:0071875 adrenergic receptor signaling pathway?
GO:0071875 is a Gene Ontology biological process term defined as a G protein-coupled receptor signaling pathway initiated by ligand binding to an adrenergic receptor on the target cell surface and ending with regulation of a downstream cellular process.
What genes are involved in adrenergic receptor signaling pathway?
Key genes include ADRB1, ADRB2, ADRB3, ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, GNAS, GNAI1, GRK2, ARRB1, and ARRB2.
What are the main steps of adrenergic receptor signaling?
The pathway begins with ligand binding to adrenergic receptors, followed by G protein activation, second messenger generation, kinase cascade activation, receptor desensitization, and regulation of downstream cellular processes.
How is adrenergic receptor signaling regulated?
It is regulated by GRK-mediated phosphorylation, beta-arrestin binding, receptor internalization, and crosstalk with other pathways such as Hippo signaling.
What diseases are associated with adrenergic receptor signaling?
Heart failure, neuroinflammation, Alzheimer's disease, pulmonary inflammation, and sleep-related ovarian dysfunction have been linked to adrenergic receptor signaling.
How can CRISPR be used to study adrenergic receptor signaling?
CRISPR knockout, point mutation, knock-in, and overexpression models allow researchers to dissect the causal roles of specific receptors and effectors in disease processes.
What is the role of beta-adrenergic receptors in heart failure?
Beta-adrenergic receptors, particularly ADRB1 and ADRB2, mediate cardiac contractility and remodeling, and their chronic overactivation contributes to heart failure progression.
What is the role of alpha1-adrenergic receptors in Alzheimer's disease?
Modulation of neuronal alpha1-adrenergic receptors reduces tauopathy and neuroinflammation by inhibiting the STING/NF-kB/NLRP3 signaling pathway in Alzheimer's disease mice.
How does sleep deprivation affect adrenergic receptor signaling in the ovary?
Sleep deprivation triggers excessive activation of ovarian primordial follicles via beta2-adrenergic receptor signaling.
What methods are used to study adrenergic receptor signaling?
Common methods include CRISPR knockout, cAMP assays, calcium imaging, RNA-seq, proteomics, FRET biosensors, immunoblotting, and co-immunoprecipitation.
Conclusion
GO:0071875 adrenergic receptor signaling pathway is a fundamental biological process that governs cellular responses to catecholamines across multiple organ systems. Its dysregulation is implicated in heart failure, neuroinflammation, pulmonary inflammation, and reproductive dysfunction, making it a high-priority target for both basic and translational research. The pathway's complexity, including receptor subtype diversity, G protein coupling, desensitization, and non-canonical signaling, requires sophisticated experimental models to dissect. CRISPR-based approaches, including knockout, point mutation, knock-in, and overexpression, provide powerful tools to causally link specific genes to pathway function and disease phenotypes. EDITGENE's comprehensive services support researchers in generating these models efficiently, accelerating discovery in adrenergic receptor signaling and its therapeutic applications.
References
- 1. Li W et al.. 2025. A brain-to-lung signal from GABAergic neurons to ADRB2(+) interstitial macrophages promotes pulmonary inflammatory responses.. Immunity 58(8):2069-2085.e9 PMID: 40466637
- 2. Li B et al.. 2025. Modulation of neuronal α1-adrenergic receptor reduces tauopathy and neuroinflammation by inhibiting the STING/NF-κB/NLRP3 signaling pathway in Alzheimer's disease mice.. J Neuroinflammation 22(1):187 PMID: 40676669
- 3. Weng L et al.. 2024. Sleep Deprivation Triggers the Excessive Activation of Ovarian Primordial Follicles via β2 Adrenergic Receptor Signaling.. Adv Sci (Weinh) 11(41):e2402393 PMID: 39229959
- 4. Ma YC et al.. 2002. Novel signaling pathway through the beta-adrenergic receptor.. Trends Cardiovasc Med 12(1):46-9 PMID: 11796245
- 5. Bencivenga L et al.. 2019. β-Adrenergic Receptor Signaling and Heart Failure: From Bench to Bedside.. Heart Fail Clin 15(3):409-419 PMID: 31079699
- 6. Du XJ et al.. 2024. Coupling of β-adrenergic and Hippo pathway signaling: Implications for heart failure pathophysiology and metabolic therapy.. Mitochondrion 78:101941 PMID: 39122227
- 7. Wei W et al.. 2022. Subcellular β-Adrenergic Receptor Signaling in Cardiac Physiology and Disease.. J Cardiovasc Pharmacol 80(3):334-341 PMID: 35881897
- 8. Benovic JL. 2002. Novel beta2-adrenergic receptor signaling pathways.. J Allergy Clin Immunol 110(6 Suppl):S229-35 PMID: 12464929
